4.225
Schlusskurs vom Vortag:
$4.26
Offen:
$4.24
24-Stunden-Volumen:
416.37K
Relative Volume:
0.28
Marktkapitalisierung:
$419.69M
Einnahmen:
$58.36M
Nettoeinkommen (Verlust:
$-25.72M
KGV:
-11.60
EPS:
-0.3641
Netto-Cashflow:
$-24.91M
1W Leistung:
-3.32%
1M Leistung:
+31.62%
6M Leistung:
+36.73%
1J Leistung:
+25.37%
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Firmenname
Aquestive Therapeutics Inc
Sektor
Telefon
908-941-1900
Adresse
30 TECHNOLOGY DRIVE, WARREN, NJ
Vergleichen Sie AQST mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AQST
Aquestive Therapeutics Inc
|
4.2253 | 394.33M | 58.36M | -25.72M | -24.91M | -0.3641 |
![]()
ZTS
Zoetis Inc
|
153.02 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.65 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.825 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.44 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
303.09 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-05-10 | Eingeleitet | Leerink Partners | Outperform |
2024-04-11 | Eingeleitet | Piper Sandler | Overweight |
2024-03-28 | Eingeleitet | Raymond James | Outperform |
2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
2019-04-22 | Eingeleitet | H.C. Wainwright | Buy |
2019-01-03 | Eingeleitet | Lake Street | Buy |
2018-08-20 | Eingeleitet | JMP Securities | Mkt Outperform |
2018-08-20 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten
Is Aquestive Therapeutics Inc. a good long term investmentFree Real-Time Stock Data - Autocar Professional
Aquestive Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
What drives Aquestive Therapeutics Inc. stock priceFree Capital Allocation Plans - Autocar Professional
What analysts say about Aquestive Therapeutics Inc. stockAccelerated profit realization - jammulinksnews.com
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - GlobeNewswire
EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer - Stock Titan
After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar - simplywall.st
Aquestive's Anaphylm to be reviewed by Health Canada - MSN
When is the best time to buy Aquestive Therapeutics Inc. stockAlpha Stock Ideas - Newser
Will Aquestive Therapeutics Inc. stock benefit from AI tech trendsFree Professional Portfolio Management - Newser
Why Aquestive Therapeutics Inc. stock attracts strong analyst attentionSteady Income Ideas - beatles.ru
Cantor Equity Partners I, Inc. shares rise 2.24% premarket after Aquestive Therapeutics' positive drug submission meeting with Health Canada. - AInvest
11,303 Shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Acquired by Cambridge Investment Research Advisors Inc. - Defense World
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film - GlobeNewswire
What makes Aquestive Therapeutics Inc. stock price move sharplyFree High-Profit Stock Picks - Newser
Aquestive's Anaphylm to be reviewed by Health Canada (AQST) - Seeking Alpha
Aquestive schedules regulatory meetings for epinephrine film in Canada, EU - Investing.com Canada
How Aquestive Therapeutics Inc. stock performs during market volatilityDaily Stock Radar - Newser
Aquestive Therapeutics Says Canadian Regulator Has Granted Meeting to Discuss Anaphylm Approval - MarketScreener
Aquestive schedules regulatory meetings for epinephrine film in Canada, EU By Investing.com - Investing.com Nigeria
Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):